DURECT Corp (DRRX) Reports In-Line Q2 EPS

Go back to DURECT Corp (DRRX) Reports In-Line Q2 EPS

DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs

July 29, 2021 4:05 PM EDT

CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.

Q2 2021 Accomplishments:

We expanded the number of U.S. clinical trial sites to 26 in the Phase 2b AHFIRM clinical study of DUR-928 in severe alcohol-associated hepatitis (AH), and... More